Fact checks · Supplements
“Can high-dose vitamin D or the Coimbra protocol stop MS?”
The bottom line
Evidence for vitamin D as an MS treatment is mixed, correcting deficiency is a separate clinical goal, and Coimbra-style mega-doses lack convincing efficacy evidence and can cause serious toxicity.
Why people are talking about it
Low vitamin D levels are associated with MS risk and disease activity, encouraging interest in supplementation. Brazilian physician Cicero Coimbra's protocol extends this idea to very high individualized doses, promoted through specialist clinics and patient networks.
What the research says
VIDAMS randomized 172 people with established relapsing-remitting MS to 5,000 or 600 IU of vitamin D3 daily alongside glatiramer acetate for 96 weeks. The higher dose did not significantly reduce clinical relapses compared with the lower dose. In contrast, the D-Lay MS double-blind trial randomized 316 people after a first demyelinating event to 100,000 IU every two weeks or placebo, with 303 included in the primary analysis. Over 24 months, the combined relapse-or-MRI disease-activity outcome occurred in 60.3% versus 74.1%, favouring vitamin D, but clinical relapse outcomes alone were not significantly different. These different populations, regimens and outcomes help explain why supplementation evidence remains mixed and do not validate Coimbra-style daily mega-doses. A 2022 uncontrolled Coimbra-protocol safety series included 319 patients with various autoimmune diseases, not an MS efficacy comparison. Its monitored laboratory findings cannot establish that the protocol treats MS or is safe in wider use.
What we don't know yet
The optimal dose and target blood level for any MS-specific benefit remain uncertain, as does which patient group might benefit. The positive early-disease trial does not establish long-term disability prevention or equivalence to an approved disease-modifying therapy.
Risks and costs
Excess vitamin D can cause high blood calcium, kidney stones and kidney injury. Severe hypercalcemia requiring hospitalization has been reported in a person with MS taking high doses. Clinic visits, repeated laboratory monitoring, supplements and dietary restrictions add cost and burden. Monitoring and calcium restriction do not turn an unproven mega-dose regimen into an established safe treatment. Do not replace or delay a proven disease-modifying therapy with vitamin D.
Questions to bring to your neurologist
- Do I have vitamin D deficiency, and what dose and blood-level target are appropriate for me?
- Do my kidney function, calcium levels, medications or stone history change the risks?
- How do the VIDAMS and D-Lay MS results apply to my disease stage without replacing my MS treatment?
Sources
- High-dose vitamin D3 supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial (RCT, 2023)
- High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial (RCT, 2025)
- Safety Data in Patients with Autoimmune Diseases during Treatment with High Doses of Vitamin D3 According to the "Coimbra Protocol" (Observational, 2022)
- What happens if you deliberately overdose on vitamin D? (Report, 2025)
This is information, not medical advice. Talk to your neurologist before changing anything.
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error